AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cleo Diagnostics Ltd

0.340

0.000

Volume:154.49K

Turnover:52.71K

Market Cap:48.41M

PE:-7.61

High:0.355

Open:0.330

Low:0.325

Close:0.340

52wk High:0.900

52wk Low:0.310

Shares:142.38M

Float Shares:73.01M

Volume Ratio:2.15

T/O Rate:0.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.045

EPS(LYR):-0.045

ROE:-109.48%

ROA:-52.15%

PB:9.66

PE(LYR):-7.61

Loading ...

Overview Company News Filings

Cleo Diagnostics - Receives First Batch of Commercially Manufactured Test Kits

THOMSON REUTERS

Cleo Diagnostics Enters Analytical Validation Phase for Ovarian Cancer Blood Test; Shares Fall 6%

MT Newswires Live

Cleo Diagnostics Outlines US Commercialization Strategy for Ovarian Cancer Test Ahead of FDA Clearance

MT Newswires Live

Cleo Diagnostics Starts Manufacturing, Development Program for Ovarian Cancer Test Kit Production; Shares Up 8%

MT Newswires Live

Cleo Diagnostics Ltd-Cleo Commences Kit Manufacturing Ahead of FDA Submission

THOMSON REUTERS

ASX Opportunities: Alcidion Group Among 3 Promising Penny Stocks

Simply Wall St.

Cleo Diagnostics Achieves Recruitment Target for US Pre-Surgical Ovarian Cancer Test Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/COV.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"COV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"COV.AU\",,,,,undefined,":{"symbol":"COV.AU","market":"AU","secType":"STK","nameCN":"Cleo Diagnostics Ltd","latestPrice":0.34,"timestamp":1789020720000,"preClose":0.34,"halted":0,"volume":154485,"delay":0,"changeRate":0,"nameEN":"Cleo Diagnostics Ltd","floatShares":73005001,"shares":142383746,"eps":-0.0447,"marketStatus":"Not Yet Opened","change":0,"latestTime":"09-10 16:12:00 AEST","open":0.33,"high":0.355,"low":0.325,"amount":52709,"amplitude":0.088235,"askPrice":0.36,"askSize":7000,"bidPrice":0.335,"bidSize":1699,"shortable":3,"etf":0,"ttmEps":-0.0447,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":0,"adr":0,"listingDate":1692540000000,"exchange":"ASX","adjPreClose":0.34,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":2.151404,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"COV.AU","preClose":0.34,"auctionPrice":0.33,"auctionVolume":5588,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020000491}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"COV.AU\",,,,,undefined,":{"symbol":"COV.AU","floatShares":73005001,"roa":"-52.15%","roe":"-109.48%","lyrEps":-0.0447,"volumeRatio":2.151404,"shares":142383746,"dividePrice":0,"high":0.355,"amplitude":0.088235,"preClose":0.34,"low":0.325,"week52Low":0.31,"pbRate":"9.66","psRate":"28.19","week52High":0.9,"institutionHeld":0,"latestPrice":0.34,"committee":-0.60938,"eps":-0.0447,"divideRate":0,"volume":154485,"delay":0,"ttmEps":-0.0447,"open":0.33,"prevYearClose":0.605,"prevWeekClose":0.385,"prevMonthClose":0.345,"prevQuarterClose":0.5,"fiveDayClose":0.4,"twentyDayClose":0.36,"sixtyDayClose":0.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COV.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COV.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"COV.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664447528","title":"Cleo Diagnostics - Receives First Batch of Commercially Manufactured Test Kits","url":"https://stock-news.laohu8.com/highlight/detail?id=2664447528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664447528?lang=en_us&edition=fundamental","pubTime":"2026-09-03 06:56","pubTimestamp":1788389776,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U19B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651198488","title":"Cleo Diagnostics Enters Analytical Validation Phase for Ovarian Cancer Blood Test; Shares Fall 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651198488","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651198488?lang=en_us&edition=fundamental","pubTime":"2026-07-13 12:44","pubTimestamp":1783917843,"startTime":"0","endTime":"0","summary":"Cleo Diagnostics  entered the analytical validation phase for its blood test for the early and accurate detection of ovarian cancer, according to a Monday Australian bourse filing.The company completed the final development and preparation activities required for the phase, including commercial assay development as well as the completion of patient recruitment and prospective blood sample collection for its pivotal US clinical trial.Analytical validation is expected to start in August upon receipt of the first manufactured batch of its test kits from Bio-Techne, per the filing. The company will evaluate three independently manufactured production batches to demonstrate assay reproducibility, manufacturing consistency, and overall analytical robustness.The company said it expects analytical validation to take around four months to complete, adding that it anticipates US Food and Drug Administration submission to occur in the first half of 2027.Cleo Diagnostics' shares fell nearly 6% in ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636899132","title":"Cleo Diagnostics Outlines US Commercialization Strategy for Ovarian Cancer Test Ahead of FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2636899132","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636899132?lang=en_us&edition=fundamental","pubTime":"2026-05-20 09:53","pubTimestamp":1779241990,"startTime":"0","endTime":"0","summary":"Cleo Diagnostics  said it plans to enter the US market immediately following anticipated Food and Drug Administration  clearance for its pre-surgical ovarian cancer test, enabling early billing and real-world utilization data capture, according to a Wednesday Australian bourse filing.The company said reimbursement will be determined via cross-walking to comparable multi-biomarker tests, which have reported reimbursements of around $500 to $900 per test, supporting initial pricing discussions.The approach represents the first step toward securing a dedicated CPT code to support long-term reimbursement and commercial scale, the filing added.The company's shares rose 1% in recent Wednesday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COV.AU","LABU","BK7067","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630328588","title":"Cleo Diagnostics Starts Manufacturing, Development Program for Ovarian Cancer Test Kit Production; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630328588","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630328588?lang=en_us&edition=fundamental","pubTime":"2026-04-28 10:50","pubTimestamp":1777344604,"startTime":"0","endTime":"0","summary":"Cleo Diagnostics  started a staged manufacturing and development program with life sciences firm Bio-Techne to support production of its ovarian cancer test kits, according to a Tuesday filing with the Australian bourse.The program will generate the test kits required for analytical validation and the evaluation of the clinical samples collected as part of the company's US study, the filing said.Data from analytical validation and clinical sample testing will form the core evidence package for the company's US Food and Drug Administration 510 submission, per the filing.Cleo Diagnostics shares rose 8% in midday trade on Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","COV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630345677","title":"Cleo Diagnostics Ltd-Cleo Commences Kit Manufacturing Ahead of FDA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2630345677","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630345677?lang=en_us&edition=fundamental","pubTime":"2026-04-28 06:26","pubTimestamp":1777328808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUEBKGSYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629065663","title":"ASX Opportunities: Alcidion Group Among 3 Promising Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2629065663","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629065663?lang=en_us&edition=fundamental","pubTime":"2026-04-22 03:02","pubTimestamp":1776798158,"startTime":"0","endTime":"0","summary":"Australian shares are poised for a modest gain, contrasting with Wall Street's recent declines, as investors navigate global uncertainties and regional developments. In this context, penny stocks—often representing smaller or newer companies—offer intriguing opportunities for growth at accessible price points. Despite being an older term, these stocks can still hold significant potential when backed by strong financial health and solid fundamentals.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8031000-choice2-main-header/1585186598236","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8031000-choice2-main-header/1585186598236"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-kyp/kinatico-shares/news/asx-opportunities-alcidion-group-among-3-promising-penny-sto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-kyp/kinatico-shares/news/asx-opportunities-alcidion-group-among-3-promising-penny-sto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7094","OBM.AU","COV.AU","AEF.AU","CGS.AU","BK7058","BK7088","BK7506","BK7067","RPL.AU","BK7132","IRI.AU","KYP.AU","EDU.AU","PPS.AU","ALC.AU","LBL.AU","BK7503","BK7061","CLX.AU","WAF.AU","BK7104","BK7016","BK7062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623718376","title":"Cleo Diagnostics Achieves Recruitment Target for US Pre-Surgical Ovarian Cancer Test Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623718376","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623718376?lang=en_us&edition=fundamental","pubTime":"2026-03-31 10:00","pubTimestamp":1774922413,"startTime":"0","endTime":"0","summary":"Cleo Diagnostics  achieved its recruitment target, with 514 blood samples collected and 624 women enrolled across 19 US sites for its clinical trial for its pre-surgical ovarian cancer test, according to a Tuesday Australian bourse filing.The trial seeks to benchmark the test against existing tools used to assess the risk of ovarian malignancy in women with an adnexal mass for whom surgery is planned. It was designed to recruit a minimum of 500 women.It is also in final discussions with a manufacturing partner to enter into a binding agreement for test kit production, after the completion of its biomarker panel optimization.Its shares fell 1% in recent trading on Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["COV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}